Images in Clinical Medicine
Lipodystrophy Induced by Antiretroviral Therapy
N Engl J Med 2005; 352:63January 6, 2005
- Article
A 51-year-old man who was positive for the human immunodeficiency virus (HIV) and had been treated with a conventional protease-inhibitor–based antiretroviral regimen for four years had wasting of the fat of the extremities and face (especially of Bichat's fat pad), abnormal deposition of fat in the neck and trunk (“bull neck”; Panels A and B), insulin resistance, and hypertriglyceridemia. The complete blood count, the hepatic profile, and the levels of thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, and prolactin were normal. The results of a dexamethasone suppression test and the 24-hour urinary cortisol level were also normal.
In a substantial proportion of HIV-infected patients who receive protease inhibitors, changes in lipid metabolism and body-fat distribution can develop after an average of 10 to 12 months of therapy.
Stephen M. Warren, M.D.
James W. May, Jr., M.D.
Massachusetts General Hospital, Boston, MA 02114-3139- Citing Articles (1)
Citing Articles
1
G. Guaraldi, I. G. Baraboutis. (2009) Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. Journal of Antimicrobial Chemotherapy 64:3, 437-440
CrossRef
